Hunter Williams
30 September 2025
Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/ Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/ 1 On 1 Coaching Application: https://hunterwilliamscoaching.carrd.co/ Book A Call With Me: https://hunterwilliamscall.carrd.co/ Supplement Sources: https://hunterwilliamssupplements.carrd.co/ Amazon Storefront: https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY Socials: Instagram: https://www.instagram.com/hunterwilliamscoaching/Podcast: https://hunterwilliamspodcast.buzzsprout.com/ Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/ In today’s video I unpack amlexanox—an old anti-inflammatory/allergy drug with surprising metabolic effects. I share my first encounter with it in the research-chem world, what I noticed subjectively, and then dive into mechanisms (IKKε/TBK1 inhibition, catecholamine resensitization, beige fat), rodent data, the Phase 2 human trial (150 mg/day), safety, dosing, who seems to respond best, and how I’m stacking it inside Bio Ignite. If your goal is fat loss with stubborn adipose inflammation, this is worth understanding. 0:00 - Welcome + what today’s video covers 0:28 - How I first found “AM Lox” browsing catalogs 1:06 - Cycling off SLU-PP-332 and first personal trial 1:40 - Noticing dryness/ab definition; early under-dosing 2:12 - 2025 “sugar diet” + hunting for FGF21 boosters 2:40 - Finding data that amlexanox increases FGF21 3:02 - Literature dosage (100–150 mg) vs my early dose 3:38 - Why I think it’s a useful fat-loss rotation tool 4:24 - Channel/hosting update + where to find my videos 5:08 - Slides start: what amlexanox is/was used for 6:00 - Core mechanism: IKKε/TBK1 → PDE3B → cAMP resistance 7:16 - IL-6→STAT3 hepatic signaling + beigeing via FGF21 8:30 - Big-picture benefits: inflammation, insulin sensitivity, glycemia 10:32 - Human data: Phase 2 trial (150 mg/day x 12 weeks) 11:10 - Modest/variable weight change; who improved most 12:37 - Practical takeaways: glycemia, liver fat, insulin sensitivity 14:12 - Dosing in practice (50 mg caps, TID = 150 mg/day) 15:12 - Responder phenotype: high adipose inflammation 16:00 - Who benefits most + variability at similar body fat 17:56 - Study roll-up and mechanism recap 18:52 - Final thoughts, use-cases, and product note (Bio Ignite) 19:54 - Thank you + where to grab the peptide cheat sheet What You'll Learn Why amlexanox can “release the brakes” on fat-burning by inhibiting IKKε/TBK1 and restoring cAMP/catecholamine responsiveness. How it raises IL-6 transiently in adipose, activates STAT3 in the liver, suppresses gluconeogenesis, and increases FGF21 to promote beige fat programs. The mouse vs. human gap: robust fat loss in mice; in humans, clearer improvements in A1c, fructosamine, liver fat, insulin sensitivity—especially when adipose inflammation is high. Dosing used in the Phase 2 trial: 50 mg TID (total 150 mg/day) for 12 weeks. Safety snapshot: no serious AEs attributed to amlexanox in metabolic trials; most common was a transient rash. Timestamps (exact to the transcript)What you’ll learn
0:00 / 0:00